Hearing Restoration Study Enters Phase 2


We first blogged about the first in-human safety study aimed at restoring hearing last January. It was one of our most read blog posts of the year. With that level of interest, we wanted to share the most recent news on this study.

The loss of inner ear hair cells is the most common cause of sensorineural hearing loss. Once these cells are damaged, they cannot grow back. This causes permanent hearing loss. Frequency Therapeutics, a U.S.-based biotechnology company, has created FX-322, a Progenitor Cell Activation (PCA™) regenerative medicine aimed at creating new inner ear hair cells in the cochlea. With the successful completion of its first in-human safety study a year ago, the company received an additional $42 million in financing to allow the research to advance to Phase 2. The company stated that top-line results from an on-going Phase 1-2 study are expected in the first half of this year. Frequency Therapeutics has received a total of $87 million.

You can read the full press release here. We will be following this study and will share updates to the research findings as news is released.